JP6382111B2 - Ｎ末端改変オリゴペプチド及びその使用 - Google Patents

Ｎ末端改変オリゴペプチド及びその使用 Download PDF

Info

Publication number
JP6382111B2
JP6382111B2 JP2014559248A JP2014559248A JP6382111B2 JP 6382111 B2 JP6382111 B2 JP 6382111B2 JP 2014559248 A JP2014559248 A JP 2014559248A JP 2014559248 A JP2014559248 A JP 2014559248A JP 6382111 B2 JP6382111 B2 JP 6382111B2
Authority
JP
Japan
Prior art keywords
ala
pro
phe
peptide
basic procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014559248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509950A5 (enExample
JP2015509950A (ja
Inventor
フランティセク・フバレク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2015509950A publication Critical patent/JP2015509950A/ja
Publication of JP2015509950A5 publication Critical patent/JP2015509950A5/ja
Application granted granted Critical
Publication of JP6382111B2 publication Critical patent/JP6382111B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/966—Elastase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/976—Trypsin; Chymotrypsin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2014559248A 2012-03-01 2013-03-01 Ｎ末端改変オリゴペプチド及びその使用 Expired - Fee Related JP6382111B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12157616.9 2012-03-01
EP12157616 2012-03-01
US201261625896P 2012-04-18 2012-04-18
US61/625,896 2012-04-18
PCT/EP2013/054177 WO2013128003A1 (en) 2012-03-01 2013-03-01 N-terminally modified oligopeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2015509950A JP2015509950A (ja) 2015-04-02
JP2015509950A5 JP2015509950A5 (enExample) 2016-04-21
JP6382111B2 true JP6382111B2 (ja) 2018-08-29

Family

ID=49081680

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014559248A Expired - Fee Related JP6382111B2 (ja) 2012-03-01 2013-03-01 Ｎ末端改変オリゴペプチド及びその使用

Country Status (5)

Country Link
US (1) US20150038435A1 (enExample)
EP (1) EP2820150A1 (enExample)
JP (1) JP6382111B2 (enExample)
CN (1) CN104136626B (enExample)
WO (1) WO2013128003A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210156925A (ko) * 2020-06-18 2021-12-28 애니젠 주식회사 유기산-올리고펩타이드 복합체를 유효성분으로 포함하는 피부 노화 및 주름 개선용 조성물

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
AU2017332408B2 (en) 2016-09-23 2022-02-10 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
BR112019016250A2 (pt) * 2017-02-06 2020-04-14 Alize Pharma Iii Sas peptídeos isolados, uso do peptídeo isolado, método para prevenção ou tratamento de um distúrbio ósseo, método para melhorar a formação óssea, método para inibir a reabsorção óssea, método para induzir a deposição óssea, método para induzir a maturação óssea, método de expandir células tronco ex vivo e composição farmacêutica
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
WO2019120639A1 (en) * 2017-12-21 2019-06-27 Bachem Holding Ag Solid phase synthesis of acylated peptides
US20210045419A1 (en) * 2018-02-20 2021-02-18 University Of Manitoba Food Protein-Derived Peptides as Bitter Taste Blockers
CA3100665A1 (en) * 2018-05-24 2019-11-28 Amolyt Pharma Heparin-binding domain of igfbp-2 in the treatment of metabolic disorders
WO2020009548A1 (ko) * 2018-07-06 2020-01-09 애니젠 주식회사 펩타이드 복합체를 유효성분으로 함유하는 미세먼지 제거 또는 흡착용 화장료 조성물
EP4211468A4 (en) 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
US20250223627A1 (en) * 2022-03-09 2025-07-10 Glympse Bio, Inc. Fluorogenic substrates for aminopeptidase detection in biofluids
WO2023196527A2 (en) * 2022-04-08 2023-10-12 SunVax mRNA Therapeutics Inc. Ionizable lipid compounds and lipid nanoparticle compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05213990A (ja) * 1991-02-27 1993-08-24 Taisho Pharmaceut Co Ltd トリペプチド誘導体
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO2000018895A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
FR2864085B1 (fr) * 2003-12-18 2010-09-17 Centre Nat Rech Scient Nouveaux modulateurs du proteasome
WO2006032705A2 (en) * 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging
PL1853620T3 (pl) * 2005-02-09 2012-07-31 Helix Biomedix Inc Heksapeptydy przeciwdrobnoustrojowe
DE102006047529A1 (de) * 2006-10-07 2008-04-10 Evonik Goldschmidt Gmbh Oligopeptide enthaltende dermatologische Zusammensetzungen zur Steigerung der Hautempfindlichkeit und der neuronalen Reizwahrnehmung
US8067532B2 (en) * 2007-01-19 2011-11-29 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
WO2008128038A2 (en) * 2007-04-13 2008-10-23 The Scripps Research Institute Methods and compositions for treating cardiac dysfunctions
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
ES2342754B1 (es) * 2008-10-03 2011-05-11 Lipotec, S.A. Peptidos utiles en el tratamiento y/o cuidado de la piel, mucosas, cuero cabelludo y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
CN102227213A (zh) 2008-11-28 2011-10-26 诺沃—诺迪斯克有限公司 适合于衍生化的胰岛素肽的口服施用的药物组合物
BR112012016853A2 (pt) 2010-01-12 2017-10-17 Novo Nordisk As "composições farmacêuticas para administração oral de peptídeos de insulina".
EP2610243A4 (en) * 2010-08-23 2014-04-02 Postech Acad Ind Found Labeling agent and amino acid sequence using same, and method for performing simultaneous quantitative analysis of multiple proteins
CN102219850A (zh) * 2011-05-03 2011-10-19 上海格尼生物技术有限公司 新的长效glp-1化合物
CN102311483A (zh) * 2011-07-13 2012-01-11 大连伊美生物科技有限公司 一种低溶血性抗菌脂肽及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210156925A (ko) * 2020-06-18 2021-12-28 애니젠 주식회사 유기산-올리고펩타이드 복합체를 유효성분으로 포함하는 피부 노화 및 주름 개선용 조성물
KR102507392B1 (ko) 2020-06-18 2023-03-08 애니젠 주식회사 유기산-올리고펩타이드 복합체를 유효성분으로 포함하는 피부 노화 및 주름 개선용 조성물

Also Published As

Publication number Publication date
CN104136626B (zh) 2017-05-03
CN104136626A (zh) 2014-11-05
EP2820150A1 (en) 2015-01-07
WO2013128003A1 (en) 2013-09-06
US20150038435A1 (en) 2015-02-05
JP2015509950A (ja) 2015-04-02

Similar Documents

Publication Publication Date Title
JP2015509950A (ja) Ｎ末端改変オリゴペプチド及びその使用
EP2758426B1 (en) Novel glucagon analogues
KR101205272B1 (ko) 아실화된 ｇｌｐ-1 화합물
JP5907999B2 (ja) 長期間作用性ペプチド類似体のための組成物
Brouwer et al. Peptido sulfonyl fluorides as new powerful proteasome inhibitors
Jasani et al. Further studies on the structural requirements for polypeptide-mediated histamine release from rat mast cells
CN110172083B (zh) 具有抗肥胖及抗糖尿病功效的肽及其的用途
EP3448417B1 (en) Insulin dimer-incretin conjugates
KR101963202B1 (ko) 옥신토모듈린 유사체
CN102933598A (zh) 新型胰高血糖素类似物
RU2741123C1 (ru) Липопептид для эффективного ингибирования вич, его производное, фармацевтическая композиция и их применение
CN103154024A (zh) 新型n末端修饰的胰岛素衍生物
ES2528496T3 (es) Nuevos análogos de péptido similar a glucagón, composición, y métodos de uso
JP2022113164A (ja) エンドソーマルｇタンパク質共役受容体のトリパータイト・モジュレーター
US20160303245A1 (en) Fatty acid derivatives of dimeric inhibitors of psd-95
CN104364262A (zh) N末端修饰的胰岛素衍生物
WO2017205309A1 (en) Insulin receptor partial agonists
UA128300C2 (uk) Спосіб одержання подвійного агоніста glp-1/глюкагону
JP3514754B2 (ja) 肝臓癌の治療
US20110143384A1 (en) Methods of peptide modification
Mercier et al. Structure primaire de la caséine αS1 bovine: Enchaînement des peptides obtenus par action du bromure de cyanogène et des peptides résultant de l'hydrolyse trypsique de la caséine αS1 maléylée
RU2589258C1 (ru) Средство пептидной структуры, ингибирующее дипептидилпептидазу-4, и фармацевтическая композиция на его основе
TWI429747B (zh) 具修飾側鏈之ｒｎａ病毒衍生胜肽及其用途
CN121219305A (zh) Ptp1b/nck1相互作用的抑制剂及其制备和使用方法
TW201307381A (zh) 新穎的ｎ－端經修飾胰島素衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180801

R150 Certificate of patent or registration of utility model

Ref document number: 6382111

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees